Issues related to the incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System.
2025 · 1st Quarter (Jan 1 - Mar 31)
ARDELYX, INC.
Filed by ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC).
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2025
- Income
- $90,000.00
- Expenses
- Not reported
- Registrant
- ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)
- Client
- ARDELYX, INC.
- Filing UUID
- 3984393c-c7b3-402e-b3ea-b6dfe3296875
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.